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Abstract
The Alzheimer’s Association hosted the second Latinos & Alzheimer’s Symposium
in May 2021. Due to the COVID-19 pandemic, the meeting was held online over 2
days, with virtual presentations, discussions, mentoring sessions, and posters. The
Latino population in the United States is projected to have the steepest increase in
Alzheimer’s disease (AD) in the next 40 years, compared to other ethnic groups. Latinos have increased risk for AD and other dementias, limited access to quality care, and
are severely underrepresented in AD and dementia research and clinical trials. The
symposium highlighted developments in AD research with Latino populations, including advances in AD biomarkers, and novel cognitive assessments for Spanish-speaking
populations, as well as the need to effectively recruit and retain Latinos in clinical
research, and how best to deliver health-care services and to aid caregivers of Latinos
living with AD.

1

INTRODUCTION

lighted current AD-related research among Latinos. Bringing these
diverse groups into the research enterprise is essential to address the

Alzheimer’s disease (AD) is the most common cause of dementia and

health disparities that put Latinos and other groups at higher risk of

has emerged as a significant societal issue and a global priority. Coun-

dementia. In addition, convening a meeting of researchers interested

tries in Latin America (LatAm) and the global community of Latinos

in Latino health strengthens their expertise, networks, and purpose.

will experience substantial increases in dementia and its associated

Due to the COVID-19 pandemic, the symposium was held virtually

impacts in the near future.1

over 2 days in May, and welcomed >1400 registrants from 39 different

US Latinos are projected to have the steepest increase in
Alzheimer’s disease and related dementias (ADRD) in the next 40
years compared to other ethnic

groups.2

countries across six continents.
As the older adult population grows around the world, so does the

Therefore, it is essential to

prevalence of AD. However, the increase in AD will not affect all peo-

involve this population in research that can improve: (1) understanding

ple equally. For example, although the prevalence of AD in the United

of the pathology of AD among Latino populations, (2) identification of

States is estimated at 1.6%, higher rates have been reported among

social and environmental factors that either increase or decrease risk

non-Hispanic Blacks and Latinos >65 years of age.2 By 2060, the AD

for this group, (3) enrollment of Latinos in clinical trials, and (4) devel-

prevalence in Latinos ≥ 65 years old is projected to increase 7-fold over

opment of models of care with tailored approaches that are culturally

current estimates.2 Although this estimate is highest among Latino

and linguistically inclusive. With this goal, in May 2021 the Alzheimer’s

populations compared to any other major ethnic/racial group, 3 out of

Association hosted the second Latinos & Alzheimer’s Symposium, in

10 Latinos say they will not live long enough to develop dementia.3

which researchers from the United States and Latin America high-

These dual realities, plus a rapidly growing disease burden within a

3
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perpetually underserved population, force public health institutions to
consider how to increase Latino participation in AD research. More-

RESEARCH-IN-CONTEXT

over, clinicians and policymakers must prioritize efforts to enhance
access to quality care and resources for the millions of Latino AD care-

States is projected to have the steepest increase in

givers.
Latinos are racially and ethnically diverse, and often reflect a mix
of culture, environment, and genetic ancestries drawn from African,
Amerindian, and European source

1. Systematic review: The Latino population in the United

populations.4

In the United States,

Latinos of Mexican descent are the largest group, followed by Puerto
Ricans, Central Americans, South Americans, and Cubans.
Although the terms to define Latinos have changed over time, for
this article we refer to ‘‘Hispanic’’ as those whose country of origin or
ancestry is from a primarily Spanish-speaking country, including Spain.
We use the term ‘‘Latinos’’ to refer to people whose country of origin
or ancestry is from Latin America. As terminology used differs between
studies, in this article we use the terms that were originally used in the
cited studies.

Alzheimer’s disease (AD)in the next 40 years, compared
to other ethnic groups. The authors report the updates
and advances in research presented at the second Latinos
& Alzheimer’s Symposium in May 2021.
2. Interpretation: Latinos have increased risk for AD and
other dementias, limited access to quality care, and are
severely underrepresented in AD and dementia research
and clinical trials. There have been developments in
research with Latino populations, including novel cognitive assessments for Spanish-speaking populations
3. Future directions: There is a need to effectively recruit
and retain Latinos in clinical research, and further understand how best to deliver health care services and to aid
caregivers of Latinos living with AD and other dementia.

2
LATINOS, AD, AND DEMENTIA—CULTURAL,
LINGUISTIC, AND PSYCHOSOCIAL FACTORS

These and other topics will be explored at the third symposium, planned for April 2022.

Prevalence estimates for ADRD among Latino populations vary widely
in the United States, with the highest rates for those with a Caribbean
background (Dominican and Puerto Rican) and the lowest for those

cognitive reserve, which would allow the brain to better cope in the

with Mexican and Central American backgrounds.5 These estimates

face of ADRD-related changes.9

are already 20 years old, though, which highlights a need for updated

Studies find both benefits and downsides to bilingualism in different

data that can reveal population-level trends in risk and caregiving, and

tasks. Cognitive benefits of bilingualism are frequently found in tasks

provide a foundation for understanding the sociocultural, cardiovascu-

of inhibitory control,10,11 which reflects executive function.12 But bilin-

lar, and genomic factors involved in Latino cognitive health.

guals show deficiencies on fluency tests compared to monolinguals.13

This need has spurred the Study of Latinos-Investigation of Neu-

Combining verbal tasks with inhibitory control, however, results in a

rocognitive Aging (SOL-INCA), which is an ancillary study of the His-

net positive effect of bilingualism.14 For example, among those with

panic Community Health Study/Study of Latinos (HCHS/SOL) focused

amnestic mild cognitive impairment (aMCI), bilinguals had better per-

on cardiovascular disease in Latinos. SOL-INCA investigates cognitive

formance than monolinguals on tasks of verbal memory that require

aging and impairment among diverse Latinos.6 Some recent findings

the control of proactive interference.15 Additionally, some evidence

suggest that Latinos of Amerindian backgrounds seem relatively pro-

suggests an effect of bilingualism on brain plasticity.16 ,17 ,18 This and

tected from the effects of the well-known apolipoprotein E (APOE) ε4

other evidence suggests bilingualism can delay the onset of dementia,

risk allele compared to Latinos of European ancestry,7 and epidemiol-

though this remains controversial.19 ,20

ogy, biomarker, and brain data suggest that vascular risk factors such as

Bilingualism may also impact cognitive test performance, indepen-

diabetes or hypertension predominate in dementias in Latinos. A cen-

dently of underlying brain and cognitive processes. In evaluating peo-

tral hypothesis is that vascular disease could increase risk in midlife,

ple for cognitive impairment, it is important to take into account their

thus impacting dementia rates later in life. This suggests that improv-

bilingual background to obtain accurate measures of task performance;

ing vascular health for middle-aged adults, which includes addressing

this may mean conducting cognitive assessments via bilingual evalua-

obesity, may reduce risk of ADRD disease burden in older Latinos.

tors, and developing neuropsychological normative data for bilinguals.

The interaction of genetic and environmental factors in the devel-

Social isolation has been shown to negatively impact physical and

opment and progression of AD is complex for the Latino population

mental health including cognitive health and dementia risk. It may be

due to the influence of lower levels of education, acculturation, socioe-

particularly detrimental for Latinos who place a high value on family

conomic conditions, immigration, language proficiency, and bilingual-

interactions. Many US Latinos live and work far from home, which

ism, among others. Many Latino adults in the United States are bilin-

can create stress and loneliness, and might ultimately lower their

gual, with 59% of those speaking English also speaking Spanish.8 As

cognitive function. To try to capture novel insights into social isolation,

language experience powerfully shapes brain and cognitive function,

a new study has leveraged data from the Texas Alzheimer’s Research

bilingualism may play an important role in one’s protection or risk to

and Care Consortium (TARCC). This registry collects longitudinal

develop dementia later in life. One idea is that bilingualism may build

clinical, genetic, biomarker data of people with AD or MCI, as well

4
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as demographic, environmental, and interpersonal data that can be

Latinos from different countries.21 Even with these changes, Latinos

used as a proxy for social isolation. Using data from nearly 300 people,

who primarily speak English outperform those who primarily speak

77% of whom identified as Latino, regression modeling found that

Spanish in multiple cognitive tasks; this is likely an effect of educational

interpersonal variables such as marital status, number of children, and

attainment, as the English-speaking Latinos had, on average, several

number of siblings had a positive, Latino-specific effect on cognition.

more years of education. Without taking education into account, a cog-

This suggests that interventions based on increasing community

nitively healthy Latino may have test scores that put them into below-

connections might benefit cognitive health in Latinos.

average ranges.

New research also points to the importance of additional psychoso-

Latinos in the United States have experienced a disproportionate

cial factors. Having a sense of purpose in life is often considered bene-

burden of COVID-19 infection, hospitalization, and COVID-19–related

ficial for cognitive health. Specifically, purpose in life refers to a sense

mortality.22 Increasing evidence suggests that an estimated 30% of

of meaning and the perception that there is value in achieving one’s

COVID-19 survivors experience memory loss23 and prolonged neuro-

goals, and this sense may reflect a healthy brain at work. The rela-

logical symptoms. A new study examined whether plasma biomarker

tionship between cognitive health and having a sense of purpose is

concentrations for amyloid beta (Aβ) pathology (Aβ40, Aβ42), axonal

being studied among older Latinos in Latin America, including sites

injury (neurofilament light), and neurodegeneration (total tau) differ

in Argentina, Chile, Dominican Republic, Mexico, and Peru, as part of

among a non-clinical population of Latinos who were also COVID-19

Massachusetts General Hospital’s Multicultural Alzheimer’s Preven-

survivors compared to non-exposed individuals. It also examined asso-

tion Program (MAPP). Using a self-reported Life Purpose question-

ciations between plasma biomarkers with neurocognitive assessments.

naire, and the Everyday Cognition scale to capture purpose in life and

Community-engaged recruitment took place at a church on eastern

subjective cognitive decline, respectively, preliminary regression anal-

Long Island. In the resulting diverse population of foreign-born Latinos

ysis results show that higher purpose in life scores predict lower per-

at mid-life, the researchers found that plasma biomarker concentra-

ceived cognitive decline, which can be a harbinger of AD. The asso-

tions for Aβ40, Aβ42/40, and total tau differed among COVID-19 sur-

ciations between purpose in life and objective measures of cognitive

vivors compared to non-exposed individuals. Plasma concentrations

decline remain unclear in these populations, but differences between

were further associated with significant decreases across domain-

countries suggest potential cultural influences.

specific cognitive assessments.
To begin understanding normal aging, cognitive decline, and AD
biomarkers in Latinos, researchers at the Harvard Aging Brain Study

3
ASSESSMENT AND BIOMARKERS IN
LATINOS—CHALLENGES AND OPPORTUNITIES

(HABS) are recruiting a sample of cognitively unimpaired older Latinos to comprehensively track their clinical, cognitive, and neuroimaging features as they age. Initial cross-sectional results showed that

There are crucial knowledge gaps about normal aging, cognitive

there were no differences in in vivo markers of Aβ or tau pathology,

decline, and the roles of AD biomarkers in the Latino population. To

or hippocampal volume between Latino and non-Hispanic White par-

understand how cognition relates to the biology of AD, assessment

ticipants. In contrast, despite having similar levels of formal education,

tools must be validated across different populations. Commonly used

Latinos had lower performance on a cognitive composite score, specifi-

neuropsychological tests may not be sensitive to cognitive changes in

cally on timed tasks, which may be partially explained by cultural differ-

Latinos in the United States who speak Spanish as their first language.

ences. These initial findings emphasize the importance of considering

Moreover, cultural factors have also been shown to influence an indi-

cultural and linguistic factors in neuropsychological assessment, and

vidual’s approach to cognitive tasks. Thus, cultural and linguistic fac-

the need to investigate cognitive and biomarker longitudinal trajecto-

tors, as well as other sociodemographic factors, need to be considered

ries among Latinos. To this end, the Boston Latino Aging Study (BLAST)

when examining cognitive performance.

seeks to investigate the impact of different AD risk factors on cogni-

Culturally appropriate cognitive assessment is a critical issue when
working with the diverse Latino populations in the United States. The

tion and brain function, including culturally appropriate, validated measures, in older Latino individuals.

network of Alzheimer’s Disease Research Centers in the United States

To understand how the development of amyloid, tau, and neurode-

contributes longitudinal data to the National Alzheimer’s Coordinating

generation (ATN) biomarkers proceeds among diverse populations, the

Center; 8% of enrollees are Latino, of whom 69% speak Spanish as their

Health and Aging Brain among Latino Elders (HABLE) has been char-

primary language. The registry collects standard clinical and cognitive

acterizing the onset and progression of ADRD biomarkers in Mex-

data called the Uniform Data Set (UDS); the data include scores on

ican Americans and non-Hispanic Whites in the Dallas–Fort Worth

common tests of memory, visuospatial abilities, processing speed, exec-

area of Texas.24–26 This has been extended to a study of Health Dis-

utive function, and language—but the instruments were all originally

parities (HABS-HD), in which 1000 Mexican Americans, 1000 non-

developed in English. Given cultural differences, the tests not only need

White Hispanics, and 1000 African Americans are being enrolled for

to be translated, but also adapted. As such, in 2017 Version 3 of the

a comprehensive evaluation of cognitive function, brain health, and

UDS battery was translated into Spanish, with adaptations to a naming

AD-related biomarkers. Some interesting differences have already

task to account for objects that are not familiar to Latinos (e.g., a port-

come to light: compared to non-Hispanic Whites, Mexican Americans

hole), and for multiple Spanish words used for the same objects among

have an earlier age of onset of MCI, which confirms earlier work,27

5
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develop neuroimaging-based signs of neurodegeneration earlier, and

advertising in the newspaper, on the radio, or on Facebook did not

yet exhibit a lower frequency of APOE ε4 alleles and lower rates of amy-

effectively reach Latinos. Instead, recruiting through health care clinics

loid positivity.

was more successful, and comprehensive clinical care is offered as part

The profile of multiple proteins in blood have different patterns in
Mexican Americans, with metabolism-related markers predominat-

of the study. This health- and family-centered research approach works
to build trust by taking time to form relationships with participants.30

ing in MCI, then shifting to inflammation-related ones in dementia,

Inspired by the success of the Finnish FINGER trial,31 the LatAm-

whereas the opposite relationship was observed in non-Hispanic

FINGERS trial aims to determine whether a similar, and culturally

Whites. Preliminary data indicate that amyloid deposition in the

adapted, multi-level lifestyle intervention provides cognitive benefits

brain, as detected by positron emission tomography scanning, occurs

for people living in 12 countries of Latin America.32 The randomized,

at a lower rate in Mexican Americans and African Americans than

controlled trial consists of a 1-year multi-domain intervention involv-

in non-Hispanic Whites, in contrast to the earlier age of onset of

ing diet, exercise, cognitive training, and vascular risk mitigation. A sec-

cognitive decline. Sociocultural factors influence these biomarkers

ond year of intervention will be held upon feasibility outcomes accom-

differently for different ethnic subgroups. For example, subjective

plishment. The study will be launched in the fall of 2021 and seeks to

memory concerns were associated with neurodegeneration markers in

enroll 100 older adults at risk of cognitive impairment from each coun-

non-Hispanic Whites, but not in Mexican Americans. These and many

try. Data will be standardized to allow data sharing with other large tri-

other measures are publicly available, which will help obtain a clearer

als, as well as to achieve harmonization within the multi-center study

picture of the complex associations between cognition and AD-related

involving the diverse Latino populations involved. This calls for flexibil-

biomarkers in different ethnic groups.

ity; for example, though the diet component of the intervention calls

First, future studies should examine biomarkers of proteinopathies

for fish, fish consumption varies widely across Latin American coun-

and neurodegeneration, as well as vascular contributions to cogni-

tries. This means that diet compliance will have to be measured in ways

tive impairment and dementias. Second, studies examining the role of

beyond simple consumption of specific food groups.

sociocultural factors, including acculturation and quality of education,

The Dominantly Inherited Alzheimer Network Trial Unit (DIAN-

are needed, as well as research that helps develop more appropriate

TU) is a global platform for clinical trials, which has recently added

cognitive tests and normative data for different Latino heritages. Third,

new sites in Mexico, Colombia, Brazil, and Argentina. These countries

explorations of the unique genomic ancestry of diverse Latinos will

were chosen because of a growing number of dominantly inherited

yield exciting and new insights into Latino health, cognitive aging, and

Alzheimer’s disease (DIAD) cases detected there, who carry mutations

impairment. Importantly, increased engagement with Latino communi-

in amyloid-related genes (e.g., PSEN1, PSEN2, and APP). These pockets

ties is essential for successfully recruiting diverse and representative

of high DIAD frequency are due to founder effects, and mostly reflect

Latinos into cognitive aging and dementia research.

mutations that originated in Europe.33 Ongoing observational studies
have laid the groundwork for clinical trials such as the Primary Prevention study, which seeks to prevent Aβ pathology in people carrying

4
CLINICAL TRIALS FOR LATINO
PARTICIPANTS—FROM BEHAVIORAL
INTERVENTIONS TO PHARMACOLOGICAL
TREATMENTS

these high-risk mutations by clearing or preventing Aβ aggregation, or
the Tau NexGen study (secondary prevention), which seeks to lower
tau tangle formation via anti-tau antibodies, small molecules, or even
gene therapies. Practical challenges come with orchestrating a study
across multiple countries, such as insufficient infrastructure for col-

Latinos comprise < 1% of clinical trials for AD.28 To engage, recruit, and

lecting biomarkers or country-specific regulations, but these are sur-

retain sufficient participant numbers to conduct well-powered studies

mountable.

focused on Latinos, researchers will have to adjust their recruitment

In the arc of a study, recruitment is often considered an

strategies, and standardize procedures for the diverse Latino popula-

afterthought, but in reality it is just as important as other com-

tions enrolled. This is true for a variety of study types, from trials test-

ponents, and directly impacts the feasibility of any study and the

ing pharmaceuticals to lifestyle interventions, as well as for genetic

generalizability of the study results. This means that the process

studies of rare, dominantly inherited variants for AD.

of recruitment warrants its own priority in the design and conduct

For example, a trial focused on targeting cellular processes under-

of clinical research. Despite the need to recruit Latinos to clinical

lying aging in individuals with AD needed to adjust recruitment strate-

trials, researchers find this challenging. To better understand these

gies to attain 40% Latino representation in its participant pool. Based

challenges, the Alzheimer’s Clinical Trials Consortium (ACTC) is using

in south Texas in the United States, the trial, called Rapamycin—Effects

a data-driven, evidence-based approach to understand potential

on Alzheimer’s and Cognitive Health (REACH) study (NCT04629495)

selection biases, through the collection and analysis of outreach data,

is testing the safety, tolerability, and feasibility of 12 months of oral

pre-screening data, and study data across all of the trials conducted by

rapamycin treatment in older adults with aMCI and early-stage AD.

the Consortium. This includes using the definition of race and ethnicity

By blocking the effects of a kinase, rapamycin promotes cell growth,

based on current US Census categories. This has enabled a more gran-

metabolism, and proliferation. Rapamycin has been shown to extend

ular view of what happens both prior to consent and post-consent, and

lifespan in multiple species, and can improve cognition in

mice.29

Dur-

ing recruitment, the researchers found that typical strategies such as

the reasons individuals are not eligible for studies, including practical
concerns about transportation or time.

6
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Another institution-level barrier to inclusive research is underrep-

for AD, but they do not know what treatments or services are avail-

resentation of Latino investigators within the workforce. The grow-

able for people with memory problems, or they have had problems nav-

ing appreciation for the importance of developing a diverse scientific

igating the health-care system and finding resources in their preferred

workforce is seen in the newly created Alzheimer’s Disease Resource

language.36

Centers for Minority Aging Research (RCMAR), which supports the

Caregivers face new challenges when a person with AD returns

priorities outlined in the 2019 ADRD Summit. Through several initia-

home after a hospital stay. This transition places those with AD at risk

tives and community engagement cores, these centers support and

for medication errors and adverse events because care is fragmented,

mentor diverse and emerging scholars in pursuit of independent scien-

information is lost in transition, and discharge instructions are miss-

tific careers focused on cognitive aging, impairment, and disorders. To

ing, not culturally tailored, or difficult to follow. Preliminary results

better understand and meet the needs of the community, researchers

from a longitudinal, in-depth qualitative study of caregivers involved

need to build trust, foster long-term relationships between academic

in hospital-to-home transitions illustrated some of their difficulties:

centers and the community, consider the needs of the community first,

worry about overmedication, resignation about the limited effective-

and partner with other established associations. One approach is to

ness of drugs, scarcity of translated and culturally specific informa-

rely on individuals and groups already in the community for data collec-

tion, wariness toward health-care providers, distress over having to lie

tion and recruitment, such as home care workers or undergraduate stu-

to a loved one to avoid unnecessarily uncomfortable situations, and a

dents. More information about RCMAR-related community engaged

lack of easily accessible information that is truly helpful. These percep-

research and recruitment of diverse older adults into AD research can

tions outline strategies for health-care systems and home health care

be found in a recent issue of Ethnicity and Disease, with a foreword from

agencies to improve care, earn trust, and develop culturally appropri-

the National Institutes of Health (NIH).34

ate information that can educate and empower Latinos with AD and

Other ways to build trust and recruit Latino participation in studies

their caregivers.

include giving results or updates from trials to participants, which

Many Latinos believe that AD is a normal part of aging, or may think

increases their sense of involvement and commitment to remain

they will not live long enough to develop AD, or would be insulted if a

in the trial. Home visits or digital technology may help circumvent

doctor suggested cognitive testing.3 This situation demands concerted

time and transportation constraints; increasing the diversity of the

outreach efforts, which can include high-tech options such as using the

study and health-care workforce can also help foster understand-

popular messaging app WhatsApp to reach people with AD informa-

ing between researchers and participants. While studies in Latin

tion, and low-tech informational flyers in restaurants frequented by

America seem to face less difficulty recruiting than in the United

Latinos. Other outreach methods make use of existing organizations,

States, reaching rural populations in these countries still presents a

such as churches, Hispanic chambers of commerce, or the Promotores

challenge.

program of the National Hispanic Council on Aging, which enlists community health workers to increase health literacy in Latino communities.

5

STRATEGIES FOR CARE AND SUPPORT

Other cultural considerations discussed included a tendency for
Latinos to wait until a crisis or an emergency occurs before seeking

The 2021 Alzheimer’s Disease Facts and Figures Special Report on

help, which may be too late for AD interventions. It would be impor-

Race, Ethnicity and Alzheimer’s in America found that one-third of

tant to encourage Latinos to ask questions to their primary care doc-

care.3

The

tors or other health-care personnel, and likewise encourage health-

Alzheimer’s Association has called for diversification of the health-care

care providers to share information about the disease and ask patients

workforce, and better education and preparation to care for a diversity

questions to improve their awareness and facilitate early diagnosis and

of patients, as well as increasing the representation of Latinos in clinical

interventions. Further, health-care personnel should give patients and

trials.

their families the opportunity to describe their symptoms in their own

Hispanics reported discrimination when seeking health

Latinos face many obstacles in getting access to health-care ser-

words, because the words used might be different from those used

vices for ADRD, which are exacerbated by lack of awareness about the

regularly by non-Hispanic Whites.37 Special care needs to be taken

condition. According to the Behavioral Risk Factor Surveillance Sys-

when health information is translated; given the diversity of languages

tem (BRFSS) only 44% of Hispanics with self-reported cognitive decline

and dialects in the United States, information needs to be culturally

would discuss their symptoms with a health-care professional,35 and

adapted and modified to match the unique characteristics of the com-

39% of those with subjective cognitive decline have experienced one

munity, including health literacy and educational attainment. Care-

or more barriers to access health-care services. Some of the most com-

givers prefer to get information from other people who have had the

mon barriers are: lack of health insurance, concerns about cost, lack of

same experience, as much of the information they receive from health

transportation, and long wait times for an appointment. Latinos also

services seems too general, and not relevant to their particular situa-

have misconceptions about dementia. Many believe that dementia is

tions. Therefore, providing caregivers support group options would be

a preliminary stage to AD, characterized by changes in behaviors, and

beneficial. It is critical to provide health-care systems with resources to

that AD is a stage where the individuals’ ability to connect and remem-

reach out to Latino populations and redesign models of care to better

ber is lost. Overall, most individuals believe it is important to seek care

suit their needs.
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MENTORING SESSIONS

7
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To ensure the workforce is representative of communities served

Project Subaward: Alzheimer’s Los Angeles; Principal Investigator,

going forward, diversifying and supporting the next generation of AD

Interdisciplinary Aging Research to Address Health Disparities in

and dementia clinicians and researchers is of utmost importance. To

Alzheimer’s Disease and Related Dementias; National Institute on

this end, the symposium included two mentoring sessions. The first

Aging(5R13AG063477); Co-Investigator, NIA AD/ADRD Health Care

session focused on career trajectories, and offered attendees the

Systems Research Collaboratory, IMPACT Collaboratory, National

opportunity to meet and engage with leading investigators in the field

Institute on Aging (1U54AG063546-01); 2019-20 Consultant, Health

in a small group setting. Topics discussed included community engage-

Equity Team (HET); NIA AD/ADRD Health Care Systems Research Col-

ment, epidemiology and public health, juggling clinical practice and

laboratory, National Institute on Aging (1U54AG063546-01); 2017

research, and the interplay between academia and industry. The sec-

Principal Investigator, A Program for Families Caring for a Loved One

ond session focused on how to build a successful career in Alzheimer’s

with Dementia (Savvy Caregiver Program) (12-2602-3600); Research

research, highlighting resources available through the NIH and fellow-

Council, USC Suzanne Dworak-Peck School of Social Work, Los Ange-

ship programs including the Global Brain Health Institute.
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Community-Based Services; St. Barnabas Senior Services & AARP, Los
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